Last 182.50 GBp
Change Today +8.00 / 4.58%
Volume 464.1K
SUMM On Other Exchanges
As of 12:29 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

summit corporation plc (SUMM) Snapshot

174.50 GBp
Previous Close
174.50 GBp
Day High
183.50 GBp
Day Low
174.50 GBp
52 Week High
03/24/14 - 237.50 GBp
52 Week Low
07/22/14 - 101.25 GBp
Market Cap
Average Volume 10 Days
-0.33 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

summit corporation plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit corporation plc (SUMM) Details

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

23 Employees
Last Reported Date: 02/20/15
Founded in 2003

summit corporation plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit corporation plc (SUMM) Key Developments

Summit Corporation Will Appoints David Wurzer as Non-Executive Director

Summit Corporation will appoint David Wurzer as Non-Executive Director. The effective date is April 23, 2015. Mr. Wurzer is currently a Non-Executive Director on the boards of Response Genetics and Special Diversified Opportunities Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals.

Summit Corporation Approves the Adoption of New Articles of Association

Summit Corporation plc announced that at its general meeting of the company held on 19 February 2015, the shareholders approved the adoption of new articles of association of the company.

Summit Corporation plc, Special/Extraordinary Shareholders Meeting, Feb 19, 2015

Summit Corporation plc, Special/Extraordinary Shareholders Meeting, Feb 19, 2015., at 12:00 GMT Standard Time. Location: offices of Fasken Martineau LLP. Agenda: To consider proposed offering of American Depositary Shares in the United States; to adopt new Articles of Association; and to consider proposed change of name to Summit Therapeutics PLC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 182.50 GBp +8.00

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT CORPORATION PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at